Literature DB >> 34267870

Novel N-Heteroaryl Quinazolin-2-amine Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34267870      PMCID： PMC8274098          DOI： 10.1021/acsmedchemlett.1c00295

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  LRRK2 at the pre-synaptic site: A 16-years perspective.

Authors:  Francesca Pischedda; Giovanni Piccoli
Journal:  J Neurochem       Date:  2021-02-05       Impact factor: 5.372

Review 2.  The Cell Biology of LRRK2 in Parkinson's Disease.

Authors:  Ahsan Usmani; Farbod Shavarebi; Annie Hiniker
Journal:  Mol Cell Biol       Date:  2021-04-22       Impact factor: 4.272

Review 3.  New hopes for disease modification in Parkinson's Disease.

Authors:  Werner Poewe; Klaus Seppi; Kathrin Marini; Philipp Mahlknecht
Journal:  Neuropharmacology       Date:  2020-04-13       Impact factor: 5.250

Review 4.  The multi-faceted role of mitochondria in the pathology of Parkinson's disease.

Authors:  Dennison Trinh; Ahmad R Israwi; Lindsay R Arathoon; Jacqueline A Gleave; Joanne E Nash
Journal:  J Neurochem       Date:  2020-09-20       Impact factor: 5.372

Review 5.  Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.

Authors:  Matthew Taylor; Dario R Alessi
Journal:  Curr Opin Cell Biol       Date:  2020-02-07       Impact factor: 8.382

Review 6.  Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.

Authors:  Susanne A Schneider; Baccara Hizli; Roy N Alcalay
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.